ArQule Message Board - Msg: 6099197

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Bernhardt who wrote (296)	10/21/1998 8:37:00 AM
From: Dr. John M. de Castro	Read Replies (1) of 399

ARQL brings Roche back into the fold biz.yahoo.com There are so few details here that it's hard to tell how good this amendment is. However, I was very worried by the announcement that Roche was withdrawing from collaboration with ARQL. This amendment is a great relief. According to ARQL, the Roche collaboration was the most advanced and the most likely to reach the clinic first. So, the announcement that Roche was withdrawing was a major setback. The fact that continuing lead optimization is part of this amendment suggests that the advanced components of the collaboration are continuing to advance. If not good news, at least this is a great anxiety reliever. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next